Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Direxion Daily S&P 500 Bear 3X Shares SPXS

The Fund seeks daily investment results before fees and expenses of 300% of the inverse or opposite of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day. The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the funds net assets (plus borrowing for investment purposes). The index is a float-adjusted, market capitalization-weighted index. The fund is non-diversified.


ARCA:SPXS - Post by User

Post by GenevaCon Apr 18, 2022 2:53am
185 Views
Post# 34609160

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS Video


FSD Pharma is delighted to announce pre-clinical findings indicating the efficacy of Lucid-MS, its flagship medication candidate, in treating Multiple Sclerosis. Lucid-MS's therapeutic potential is an industry first, and we'd like to provide visual evidence of functional recovery in pre-clinical individuals in this video!

<< Previous
Bullboard Posts
Next >>